uniQure (QURE) Stock Price, News & Analysis

Company Overview

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease. The company leverages its scalable manufacturing capabilities and in-house process development teams to optimize vector production and ensure supply chain robustness. Through strategic partnerships and collaborations, uniQure also explores ex vivo approaches for oncology and the engineering of next-generation AAV capsids to broaden its therapeutic reach.

Founded in 1998 as a spin-off from academic research in the Netherlands, uniQure has built a transatlantic presence with its corporate headquarters in Lexington, Massachusetts, and its European research and manufacturing operations in Amsterdam. This geographic footprint enables the company to engage with leading clinical centers and regulatory authorities across North America and Europe, while advancing global registration strategies for its therapies.

The company’s leadership team is led by President and Chief Executive Officer Jeroen Louwerse, who brings extensive experience in gene and cell therapy development. Under his guidance, uniQure continues to invest in research and manufacturing infrastructure and to expand its scientific collaborations. The company remains committed to delivering durable, one-time treatments that have the potential to transform the standard of care for patients with serious genetic disorders.

Key Stats

• Today's Range: $24.00 to $25.52
• 50-Day Range: $14.73 to $29.17
• 52-Week Range: $8.73 to $71.50
• Volume: 1.22 million shs
• Average Volume: 2.05 million shs
• Market Capitalization: $1.59 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $42.83
• Consensus Rating: Moderate Buy

uniQure Stock Analysis - MarketRank™

uniQure scored higher than 70% of companies evaluated by MarketBeat, and ranked 234th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

uniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on no strong buy ratings, 10 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

uniQure has a consensus price target of $42.83, representing about 70.3% upside from its current price of $25.15.

Amount of Analyst Coverage

uniQure has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for uniQure are expected to grow in the coming year, from ($3.68) to ($3.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of uniQure is -7.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of uniQure is -7.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

uniQure has a P/B Ratio of 10.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.96% of the float of uniQure has been sold short.

Short Interest Ratio / Days to Cover

uniQure has a short interest ratio ("days to cover") of 7.03.

Change versus previous month

Short interest in uniQure has recently decreased by 2.82%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

uniQure does not currently pay a dividend.

Dividend Growth

uniQure does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.96

News Sentiment

uniQure has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for uniQure this week, compared to 13 articles on an average week.

Search Interest

20 people have searched for QURE on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,406,757.00 in company stock.

Percentage Held by Insiders

4.79% of the stock of uniQure is held by insiders.

Percentage Held by Institutions

78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/26/2026
• Next Earnings (Estimated): 8/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:QURE
• CIK: 1590560
• Web: www.uniqure.com
• Phone: (120) 240-6000
• Fax: 31-20-566-9272
• Employees: 500
• Year Founded: 1868

Price Target and Rating

• Average Price Target for uniQure: $42.83
• High Price Target: $95.00
• Low Price Target: $9.00
• Potential Upside/Downside: +70.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.53
• Research Coverage: 17 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.48)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$198.97 million
• Net Margins: -1,154.42%
• Pretax Margin: -1,123.34%
• Return on Equity: -145.81%
• Return on Assets: -27.15%

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 10.40
• Quick Ratio: 10.40

Sales & Book Value

• Annual Sales: $16.10 million
• Price / Sales: 98.52
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.37 per share
• Price / Book: 10.61

Miscellaneous

• Outstanding Shares: 63,070,000
• Free Float: 60,045,000
• Market Cap: $1.59 billion
• Optionable: Optionable
• Beta: 0.87